Lunai Bioworks Inc.
NASDAQ: RENB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David H. Weinstein
- Employees
- 25
- Headquarters
- Los Angeles, United States
- IPO year
- 2018
- Market cap
- $32.9M
- Website
- https://renovarogroup.com
Loading RENB…
Loading profile data…Frequently asked questions about RENB
What does Lunai Bioworks Inc. (RENB) do?
Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions. The company's development pipeline feature...
Where does RENB trade?
Lunai Bioworks Inc. (RENB) trades on the NASDAQ Capital Market.
What sector is RENB in?
Lunai Bioworks Inc. (RENB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lunai Bioworks Inc.?
David H. Weinstein is the chief executive officer of Lunai Bioworks Inc. (RENB).
Where is Lunai Bioworks Inc. headquartered?
Lunai Bioworks Inc. is headquartered in United States.
Does RENB pay a dividend?
Lunai Bioworks Inc. (RENB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RENB go public?
Lunai Bioworks Inc. (RENB) completed its initial public offering in 2018.